Drugs / HB-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03629080 | Dec 2018 → Jun 2022 | cytomegalovirus infection | Hookipa Biotech GmbH | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02798692 Comparator | Jun 2016 → May 2017 | cytomegalovirus infection | Hookipa Biotech GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03629080 ↗ |
| Modality | Vaccine | “HB-101 is a bivalent vaccine” NCT02798692 ↗ |
| Route | Intramuscular | “Three intra muscular administrations at Day 0, Month 1 and Month 3” NCT02798692 ↗ |